Tandem Diabetes Care, Inc. (TNDM) is a publicly traded Healthcare sector company. As of May 21, 2026, TNDM trades at $14.85 with a market cap of $927.20M and a P/E ratio of -10.46. TNDM moved +8.51% today. Year to date, TNDM is -35.03%; over the trailing twelve months it is -36.05%. Its 52-week range spans $9.98 to $45.28. Analyst consensus is buy with an average price target of $30.76. Rallies surfaces TNDM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Tandem Diabetes Care Exceeds $1B Sales, Prepares Three New Pump Launches: Tandem Diabetes Care exceeded $1 billion in 2025 sales, launched Control-IQ Plus, t:slim X2 compatibility with FreeStyle Libre and Android control for Mobi. It will launch an international Mobi rollout, U.S. Mobi with FreeStyle Libre 3 Plus and global Dexcom 15-day sensor integration on its pumps.
| Metric | Value |
|---|---|
| Price | $14.85 |
| Market Cap | $927.20M |
| P/E Ratio | -10.46 |
| EPS | $-1.40 |
| Dividend Yield | 0.00% |
| 52-Week High | $45.28 |
| 52-Week Low | $9.98 |
| Volume | 2.14K |
| Avg Volume | 0 |
| Revenue (TTM) | $1.03B |
| Net Income | $-94.55M |
| Gross Margin | 54.93% |
18 analysts cover TNDM: 0 strong buy, 9 buy, 9 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $30.76.